文献速递新药、器械与细胞基因治疗研发流行病学与生物统计

FDA医疗器械监管与审批:1976-2020年

FDA Regulation and Approval of Medical Devices: 1976-2020.
PubMed 文献 · JAMA · 2021-01-01

该综述回顾了1976至2020年美国医疗器械监管法律与标准的发展及审批结果。研究发现监管路径更复杂、证据要求差异大,FDA行业用户费增加反映效率与安全间的张力。

要点

  • 1976年起FDA实施上市前审查,后续引入加速通道与灵活证据要求。
  • 1987-2020年每年获批的新颖器械上市前批准数中位32个,510(k)许可中位3404个。

核心结论

  • 过去45年医疗器械监管更复杂,路径更多且授权所需证据与控制差异更大。
  • 行业支持增加与对灵活授权要求的担忧,反映了高效准入与安全受益保证间的张力。

研究设计与样本

  • 证据综述:审查美国国会1976至2020年颁布的法律、FDA发布的法规、FDA器械授权数据库及行业用户费年报。

主要发现

  • 1987至2020年,每年获批的新颖器械上市前批准(不含补充申请)数在8至56之间(中位数32)。
  • 1987至2020年,510(k)器械(与已上市器械“实质等同”)的许可数在2804至5762之间(中位数3404)。
  • 许多新器械带来显著患者获益(如皮下注射针和磁共振成像仪),但部分器械(如植入式避孕装置和盆腔器官脱垂外科补片)导致重要不良事件,引发重新审视监管体系的呼声。

关键数值与推荐

  • 高风险器械上市前通常需测试,中风险器械需上市前评估,目标为确保获益大于风险。

临床怎么用

  • 临床医生应了解器械审批路径差异大,对新颖器械需关注其证据强度与上市后安全性。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: US law generally requires testing of high-risk medical devices prior to approval, as well as premarket evaluation of moderate-risk medical devices, with the goal of ensuring that the benefits of these products exceed their risks. The US Food and Drug Administration (FDA) attempts to balance the need for evidence generation with an approval process that facilitates access and encourages innovation. OBJECTIVE: To review the development of laws and standards affecting the evaluation and oversight of medical devices by the US regulatory system and the outcomes of this system from 1976 to 2020. EVIDENCE REVIEW: Laws enacted by US Congress and regulations promulgated by the FDA through 2020; databases maintained by the FDA of device authorizations from 1976 to 2020; and annual reports of user fees paid to the FDA by industry. FINDINGS: Since Congress and the FDA initiated premarket review of medical devices in 1976, some fundamental innovations in the device regulation system have included special pathways to accelerate availability of investigational devices, more flexible evidence and review requirements, and increased funding to the FDA through industry-paid user fees. From 1987 to 2020, the annual number of novel devices granted premarket approval (which excludes supplements) ranged from 8 to 56 (median, 32), and the number of clearances for 510(k) devices (those that are "substantially equivalent" to marketed devices) ranged from 2804 to 5762 (median, 3404). User fee funding for devices was established in 2002 and annual fees collected increased from $30 million in 2003 (in 2019 dollars) to more than $208 million in 2019; this represented 43% of FDA funding related to the review of medical devices. Although many new devices have led to considerable patient benefit, such as hypodermic needles and magnetic resonance imaging machines, important adverse events caused by some devices, such as an implanted device for birth control and a surgical mesh implant for pelvic organ prolapse, have led to calls to reexamine the regulatory system for such products. CONCLUSIONS AND RELEVANCE: Over the last 45 years, medical device regulation has become more complex, with more regulatory pathways and greater variations in the evidence and controls required for authorization. Increased FDA support from industry and concern about flexible authorization requirements reflect the tension between efficient access and the need for assurances that products will safely benefit patients.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Darrow JJ, Avorn J, Kesselheim AS, et al. FDA Regulation and Approval of Medical Devices: 1976-2020. JAMA. 2021. PMID: 34342614. doi:10.1001/jama.2021.11171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。